Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a ...

The five muscarinic acetylcholine receptors (mAChRs) are prototypical class A G protein-coupled receptors (GPCRs). mAChRs regulate many fundamental functions of the central and peripheral nervous ...

MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel ...

Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers ...

The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally ...

Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side-effect ...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. ("Neurocrine”) ...

Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does ...

Key roles in modulating cognition and behavior made the M1 muscarinic acetylcholine receptor (mAChR) a prime target for Alzheimer disease drug developers dating back nearly two decades. However, ...